Sign up USA
Proactive Investors - Run By Investors For Investors

Exelixis shares soar on news FDA grants priority review to its kidney cancer drug

Kidney cancer is one of the top 10 most common forms of cancer in the U.S., the company said
dialysis
If the biotech wins FDA approval, it will be able to make changes to the product label, including modifications to the indication.

Biotech Exelixis Inc. (NASDAQ:EXEL) saw its shares surge in premarket trade on Monday after the U.S. Food and Drug Administration granted priority review status for its supplemental New Drug Application (sNDA) for the treatment for advanced renal cell carcinoma (RCC).

In a statement, the company said the sNDA is based on results from a mid-stage trial of Cabometyx, and is aimed at patients with previously untreated advanced RCC.

READ: Exelixis to start new combo cancer trials with Bristol-Myers and Roche

If the biotech wins FDA approval, it will be able to make changes to the product label, including modifications to the indication.

Cabometyx was given the green light by the FDA in April of 2016 for the treatment of patients with advanced RCC who have received prior anti-angioegenic therapy, or drugs that stop tumors from growing their own blood vessels.

Kidney cancer is one of the top 10 most common forms of cancer in the U.S., the company said.

In premarket trade, its shares surged 23.63% at US$30.61.

View full EXEL profile View Profile

Exelixis Timeline

Related Articles

couple looking at pregnancy test
November 13 2017
The proceeds from the fundraiser will be used to expand in the People's Republic and will invested in product development
the word antioxidant
August 15 2017
The heparin test is the firm’s lead product; however the company’s OxiChek device for oxidative stress is also gaining traction
ventripoint_device.png
June 21 2017
The device can give accurate and rapid volumetric information about all four chambers of the heart

No investment advice

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is suitable or advisable for any specific person. You understand that the Company receives either monetary or securities compensation for our services. We stand to benefit from any volume this write-up may generate.

You further understand that none of the information providers or their affiliates will advise you personally concerning the nature, potential, advisability, value or suitability of any particular security, portfolio of securities, transaction, investment strategy, or other matter.

You understand that the Site may contain opinions from time to time with regard to securities mentioned in other products, including company related products, and that those opinions may be different from those obtained by using another product related to the Company. You understand and agree that contributors may write about securities in which they or their firms have a position, and that they may trade such securities for their own account. In cases where the position is held at the time of publication and such position is known to the Company, appropriate disclosure is made. However, you understand and agree that at the time of any transaction that you make, one or more contributors may have a position in the securities written about. You understand that price and other data is supplied by sources believed to be reliable, that the calculations herein are made using such data, and that neither such data nor such calculations are guaranteed by these sources, the Company, the information providers or any other person or entity, and may not be complete or accurate.

From time to time, reference may be made in our marketing materials to prior articles and opinions we have published. These references may be selective, may reference only a portion of an article or recommendation, and are likely not to be current. As markets change continuously, previously published information and data may not be current and should not be relied upon.

Copyright © Proactiveinvestors.com, 2017. All Rights Reserved - Proactive Investors North America Inc., Proactive Investors LLC

Market Indices, Commodities and Regulatory News Headlines copyright © Morningstar. Data delayed 15 minutes unless otherwise indicated. Terms of use